{"doi":"10.1210/jendso/bvag001","title":"Assessment of N/L ratio and subclinical atherosclerosis in FH subjects with or without LDLR mutation","abstract":"<jats:title>Abstract</jats:title>\n                  <jats:sec>\n                    <jats:title>Background</jats:title>\n                    <jats:p>Familial hypercholesterolemia (FH) is a genetic disorder characterized by elevated low-density lipoprotein-cholesterol (LDL-C) and increased cardiovascular risk. While the role of LDL-C in atherogenesis is well established, the contribution of inflammatory activation in FH, particularly in relation to genotype, remains poorly defined. We aimed to evaluate the impact of genotype on neutrophil-to-lymphocyte ratio (NLR) and on subclinical atherosclerosis in a cohort of FH subjects.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods</jats:title>\n                    <jats:p>We conducted a cross-sectional study on 423 FH subjects not on lipid-lowering therapy and free from atherosclerotic cardiovascular disease. Biochemical, genetic, and vascular assessments were performed in all participants. The population was divided into 2 groups based on genotype: low-density lipoprotein receptor (LDLR; n = 273) and non-LDLR (NLDLR, n = 150). Vascular profile was assessed by coronary artery calcium score and carotid/femoral plaque presence. NLR was calculated from peripheral blood counts.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Results</jats:title>\n                    <jats:p>The LDLR group exhibited an higher NLR (2.27 ± 0.86 vs 2.05 ± 0.68, P &amp;lt; .05) than the NLDLR group. LDL-C levels and LDLR genotype were significantly associated with NLR (both P &amp;lt; .05). Multiterritorial plaque involvement was more frequent in the LDLR group than the NLDLR group (P for trend &amp;lt;.05). Age (P &amp;lt; .001), LDL-C (P &amp;lt; .001), smoking status (P &amp;lt; .05), and NLR (P &amp;lt; .05) were independently associated with subclinical atherosclerosis.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion</jats:title>\n                    <jats:p>FH subjects with LDLR mutations had a higher NLR and a more severe atherosclerosis distribution. Our findings support the role of NLR as a noninvasive biomarker of early immune activation and highlights the importance of lipoinflammatory status evaluation in FH subjects.</jats:p>\n                  </jats:sec>","journal":"Journal of the Endocrine Society","year":2026,"id":608142,"datarank":0.3958585994422889,"base_score":2.639057329615259,"endowment":2.639057329615259,"self_citation_contribution":0.3958585994422889,"citation_network_contribution":0.0,"self_endowment_contribution":0.3958585994422889,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":13,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1561748,"name":"Giosiana Bosco","orcid":"0009-0004-6036-927X","position":1,"is_corresponding":false},{"id":1561749,"name":"Maurizio Di Marco","orcid":"0000-0001-9021-6101","position":2,"is_corresponding":false},{"id":1561750,"name":"Sabrina Scilletta","orcid":"0009-0001-9061-0368","position":3,"is_corresponding":false},{"id":1561751,"name":"Nicoletta Miano","orcid":"0000-0003-0429-9807","position":4,"is_corresponding":false},{"id":1561752,"name":"Marina Martedì","orcid":null,"position":5,"is_corresponding":false},{"id":1561753,"name":"Ivan Privitera","orcid":"0000-0003-3687-0051","position":6,"is_corresponding":false},{"id":1561754,"name":"Maria Chiara Papa","orcid":null,"position":7,"is_corresponding":false},{"id":1561755,"name":"Chiara Piazza","orcid":null,"position":8,"is_corresponding":false},{"id":1561756,"name":"Francesca Valenza","orcid":null,"position":9,"is_corresponding":false},{"id":1561757,"name":"Giovanni Pennisi","orcid":null,"position":10,"is_corresponding":false},{"id":1561758,"name":"Ernestina Marianna De Francesco","orcid":"0000-0002-2810-6128","position":11,"is_corresponding":false},{"id":1561759,"name":"Roberta Malaguarnera","orcid":"0000-0003-4149-9488","position":12,"is_corresponding":false},{"id":1561761,"name":"Antonino Di Pino","orcid":"0000-0003-1705-2782","position":13,"is_corresponding":false},{"id":1561762,"name":"Salvatore Piro","orcid":"0000-0002-1781-0902","position":14,"is_corresponding":false},{"id":1561764,"name":"Roberto Scicali","orcid":"0000-0002-7023-3649","position":15,"is_corresponding":false},{"id":1561747,"name":"Francesco Di Giacomo Barbagallo","orcid":"0009-0007-2746-8104","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-30T07:33:58.699978Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}